Buspar Drug Settlement in Antrust suits Against Bristol Myers Squib By States

Kansas, Idaho, Rhode Island, and Michigan are just four out of thirty-four states that have recently obtained settlements from Bristol Meyer Squib and Danville Pharmacal for violating the antitrust act in preventing the entry of generic alternatives to Buspar, an anti-anxiety drug.   In addition to a cash payment, the drug companies agree not to list in the FDA Orange Book Buspar or other patented drugs that may delay the entry of generics onto the market.